Kristina Burow

Kristina Burow is a managing director with ARCH Venture Partners where she focuses on the creation and development of biotechnology and pharmaceutical companies. Since joining ARCH in 2002, Ms. Burow has played a significant role in the creation and development of a number of companies. In addition to Autobahn, Ms. Burow is a director of Vir Biotechnology (VIR), Vividion Therapeutics, Gossamer Bio (GOSS), ROME Therapeutics, BlackThorn Therapeutics, Metacrine, Scholar Rock (SRRK), Unity Biotechnology (UBX), Beam Therapeutics (BEAM), Boundless Bio and AgBiome. She previously was a co-founder and director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Erasca, Mindstrong, Kura Oncology (KURA), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Ikaria (acquired by Mallinckrodt). Prior to joining ARCH, Ms. Burow was an associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed chemistry operations and was active in business development where she helped create numerous companies as spinouts from GNF. Ms. Burow holds an MBA from the University of Chicago, an M.A. in chemistry from Columbia University and a B.S. in chemistry from the University of California, Berkeley.